HK1157814A1 - Materials and methods relating to cell based therapies - Google Patents

Materials and methods relating to cell based therapies

Info

Publication number
HK1157814A1
HK1157814A1 HK11112014.4A HK11112014A HK1157814A1 HK 1157814 A1 HK1157814 A1 HK 1157814A1 HK 11112014 A HK11112014 A HK 11112014A HK 1157814 A1 HK1157814 A1 HK 1157814A1
Authority
HK
Hong Kong
Prior art keywords
materials
cell based
based therapies
methods relating
cell
Prior art date
Application number
HK11112014.4A
Other languages
English (en)
Inventor
Paul Shiels
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Publication of HK1157814A1 publication Critical patent/HK1157814A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
HK11112014.4A 2008-05-09 2011-11-07 Materials and methods relating to cell based therapies HK1157814A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5209808P 2008-05-09 2008-05-09
PCT/GB2009/001149 WO2009136168A1 (en) 2008-05-09 2009-05-08 Materials and methods relating to cell based therapies

Publications (1)

Publication Number Publication Date
HK1157814A1 true HK1157814A1 (en) 2012-07-06

Family

ID=40935531

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112014.4A HK1157814A1 (en) 2008-05-09 2011-11-07 Materials and methods relating to cell based therapies

Country Status (6)

Country Link
US (2) US20110158961A1 (ko)
EP (1) EP2283115A1 (ko)
JP (1) JP2011519574A (ko)
CN (1) CN102083964B (ko)
HK (1) HK1157814A1 (ko)
WO (1) WO2009136168A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011288262A1 (en) 2010-08-13 2013-04-04 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related microRNAs
CN113265370A (zh) * 2012-06-26 2021-08-17 塞拉克西斯股份有限公司 可用于治疗胰岛素依赖性糖尿病的干细胞和胰腺细胞
WO2014091373A1 (en) 2012-12-11 2014-06-19 The University Court Of The University Of Glasgow Cellular and molecular therapies for peripheral vascular disease
AU2017240591B2 (en) * 2016-03-30 2023-08-24 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
WO2019060548A1 (en) * 2017-09-20 2019-03-28 Mora Sergio METHOD FOR EXPANSION OF HUMAN PANCREATIC PROGENITOR CELLS FROM STEM CELLS USING MEDIA CONDITIONED BY NOURISHED CELLS
JP7329265B2 (ja) * 2018-09-21 2023-08-18 アプステム セラピューティクス、インコーポレイテッド ヒト多能性成人幹細胞
JP7469317B2 (ja) 2019-01-23 2024-04-16 アステリアス バイオセラピューティクス インコーポレイテッド ヒト多能性幹細胞からの背側由来オリゴデンドロサイト前駆細胞
CN113710285A (zh) * 2019-03-26 2021-11-26 宾州研究基金会 用于治疗癌症的方法和材料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012653A1 (en) * 1997-12-19 2002-01-31 Kevin Pang Bile duct progenitor cells and methods of use
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
AU2002336742B2 (en) * 2001-09-20 2008-01-03 Anticancer, Inc. Nestin-expressing hair follicle stem cells
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
GB0509748D0 (en) * 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies

Also Published As

Publication number Publication date
JP2011519574A (ja) 2011-07-14
US20130280219A1 (en) 2013-10-24
WO2009136168A1 (en) 2009-11-12
EP2283115A1 (en) 2011-02-16
CN102083964B (zh) 2013-06-12
CN102083964A (zh) 2011-06-01
US20110158961A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
HK1157814A1 (en) Materials and methods relating to cell based therapies
CY1121383T1 (el) Μεθοδος κατευθυνομενης διαφοροποιησης που παραγει κερατοειδικα ενδοθηλιακα κυτταρα
EP2365816A4 (en) COMPOSITION WITH MECHANISM STAMMING CELLS OR BREATHING SOLUTION FOR MESENCHYM STAMMING CELLS FOR THE PREVENTION OR TREATMENT OF NERVOUS DISEASES
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
PH12014501429A1 (en) Differentiation of human embryonic stem cells into single hormonal insulin positive cells
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
GB2434157A (en) Platelets from stem cells
WO2013025446A3 (en) Anti-fzd10 monoclonal antibodies and methods for their use
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
WO2011082038A3 (en) Improved reprogramming compositions
NZ591293A (en) Methods and compositions for treatment of bone defects with osteogenic placental adherent cells (OPACs)
SG155236A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2008151058A3 (en) Methods of generating pluripotent cells from somatic cells
WO2012006440A3 (en) Endothelial cell production by programming
BR112014027783A2 (pt) diferenciação de células-tronco embrionárias humanas em endoderma pancreático
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
WO2011163531A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
EA201992135A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
MX2011007936A (es) Metodos para regeneracion de tejido pancreatico.
WO2012135842A3 (en) A unique population of regulatory t cells that regulate tissue regeneration and wound healing

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170508